Published in Proc Natl Acad Sci U S A on April 14, 2014
Immunotherapy Study for Surgically Resected Pancreatic Cancer | NCT01072981
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther (2015) 0.83
Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum. Sci Rep (2016) 0.81
ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget (2015) 0.79
Competition between serum IgG, IgM, and IgA anti-glycan antibodies. PLoS One (2015) 0.79
Diverse molecular recognition properties of blood group A binding monoclonal antibodies. Glycobiology (2016) 0.78
Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine. ACS Chem Biol (2015) 0.77
The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol (2015) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins. Cell Chem Biol (2016) 0.75
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75
Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy. PLoS One (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet (2006) 16.12
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
Cancer immunotherapy comes of age. Nature (2011) 12.35
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov (2005) 6.14
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A (2002) 3.73
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86
A study of the cellular distribution of Forssman antigen in various species. J Immunol (1956) 2.83
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology (2007) 1.84
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
Glycan microarrays for decoding the glycome. Annu Rev Biochem (2011) 1.81
High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl (2006) 1.78
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Glycan arrays: recent advances and future challenges. Curr Opin Chem Biol (2009) 1.52
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother (2011) 1.41
HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol (2009) 1.40
Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res (2009) 1.39
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol (2011) 1.26
Blood group A active substances in embryonated chicken eggs and their relation to egggrown virus. Science (1962) 1.25
Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem (2005) 1.24
Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res (2006) 1.18
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13
Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med (1992) 1.07
Characterization of the human Forssman synthetase gene. An evolving association between glycolipid synthesis and host-microbial interactions. J Biol Chem (1999) 1.04
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother (1996) 1.00
Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res (2005) 0.98
Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res (2010) 0.96
Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother (2009) 0.93
Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol (2001) 0.93
Construction and use of glycan microarrays. Curr Protoc Chem Biol (2010) 0.93
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res (2007) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Forssman expression on human erythrocytes: biochemical and genetic evidence of a new histo-blood group system. Blood (2012) 0.91
IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol (1999) 0.88
Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer (1998) 0.87
The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade. Zoonoses Public Health (2009) 0.82
Early chicken blood group investigations. Immunogenetics (1984) 0.81
Immunological markers of cancer vaccine efficacy and their clinical relevance. Biomark Med (2009) 0.79
Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation. Eur J Immunol (2007) 0.79
[BLOOD GROUP A-LIKE FORSSMAN ANTIGENS IN MYXOVIRUSES CULTURED IN A CHICKEN EGG: THEIR POSSIBLE PATHOGENETIC SIGNIFICANCE IN VACCINES]. Klin Wochenschr (1964) 0.78
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest (2010) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology (2007) 1.84
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl (2006) 1.78
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res (2007) 1.65
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Glycan arrays: recent advances and future challenges. Curr Opin Chem Biol (2009) 1.52
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J Proteome Res (2009) 1.45
Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 1.44
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res (2009) 1.39
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res (2012) 1.38
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 1.34
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Carbohydrate microarrays. Chem Soc Rev (2012) 1.25
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol (2002) 1.24
Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem (2005) 1.24
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother (2011) 1.18
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17